<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">Paediatr Respir Rev</span><span class="iso-abbrev" title="iso-abbrev">Paediatr Respir Rev</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Paediatric Respiratory Reviews</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">1526-0542</span><span class="issn-epub" tagx="issn" title="issn-epub">1526-0550</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Elsevier Ltd.</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7301825">7301825</a></span><span class="publisher-id" title="publisher-id">S1526-0542(20)30095-6</span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1016/j.prrv.2020.06.010">10.1016/j.prrv.2020.06.010</a></span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Article</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Vaccines for COVID-19: the current state of play</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koirala</span><span class="given-names" tagx="given-names" title="given-names">Archana</span></span><span class="email" tagx="email" title="email">Archana.Koirala@health.nsw.gov.au</span><a href="#af005">a</a><a href="#af010">b</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jin Joo</span><span class="given-names" tagx="given-names" title="given-names">Ye</span></span><span class="email" tagx="email" title="email">YeJin.Joo@health.nsw.gov.au</span><a href="#af005">a</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khatami</span><span class="given-names" tagx="given-names" title="given-names">Ameneh</span></span><span class="email" tagx="email" title="email">ameneh.khatami@health.nsw.gov.au</span><a href="#af015">c</a><a href="#af020">d</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chiu</span><span class="given-names" tagx="given-names" title="given-names">Clayton</span></span><span class="email" tagx="email" title="email">clayton.chiu@health.nsw.gov.au</span><a href="#af005">a</a><a href="#af015">c</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Britton</span><span class="given-names" tagx="given-names" title="given-names">Philip N</span></span><span class="email" tagx="email" title="email">philip.britton@health.nsw.gov.au</span><a href="#af015">c</a><a href="#af020">d</a><a href="#cor1">â�Ž</a></span><span class="citation_author_institution" id="af005">[a], </span><span class="citation_author_institution" id="af010">[b], </span><span class="citation_author_institution" id="af015">[c], </span><span class="citation_author_institution" id="af020">[d], </span></div> <div class="author-notes" title="author-notes"> <div class="corresp" title="corresp"><span class="label" tagx="label" title="label">â�Ž</span>Corresponding author at: C/o Discipline Child and Adolescent Heath, The Childrenâ€™s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia. <span class="email" tagx="email" title="email">philip.britton@health.nsw.gov.au</span></div> </div><span class="pub-date-pmc-release" title="pub-date-pmc-release">pmc-release: <span>2020-6-6</span></span><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-6-6</span></span><span class="history" title="history"><span class="received" title="received">received: 2020-6-11</span><span class="accepted" title="accepted">accepted: 2020-6-11</span></span><div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">Elsevier Ltd</span>, <span class="copyright-year" tagx="copyright-year" title="copyright-year">2020</span></span><span class="license" title="license"><span class="license-p" title="license-p">Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</span></span></div> <div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <p>There is a strong consensus globally that a COVID-19 vaccine is likely the most effective approach to sustainably controlling the COVID-19 pandemic. An unprecedented research effort and global coordination has resulted in a rapid development of vaccine candidates and initiation of trials. Here, we review vaccine types, and progress with 10 vaccine candidates against SARS-CoV-2 â€" the virus that causes COVID-19 - currently undergoing early phase human trials. We also consider the many challenges of developing and deploying a new vaccine on a global scale, and recommend caution with respect to our expectations of the timeline that may be ahead.</p> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
Covid 19</div> <div class="kwd" title="kwd">
vaccines</div> <div class="kwd" title="kwd">
human trials</div> <div class="kwd" title="kwd">
timeline</div> </div> </div> </div> <div class="body" title="body"> <div class="introduction:" title="sec"> <div class="title" tagx="title" title="title">
Introduction:</div> <p id="p0005">COVID-19 is the disease caused by a novel betacoronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). The disease was first reported in December 2019 Wuhan, China <a href="#b0005">[1]</a> and the full genome was sequenced and published by January 05, 2020 <a href="#b0010">[2]</a>. By March 11, 2020, COVID-19 had spread globally and was declared a pandemic, with, at the time of writing, June 6<sup>th</sup> 2020, there has been over 6 million people infected and 380,000 deaths <a href="#b0015">[3]</a>.</p> <p id="p0010">The disease primarily affects the respiratory tract and disease severity can range from very mild rhinorrhoea to severe acute respiratory distress syndrome and death <a href="#b0020">[4]</a>, <a href="#b0025">[5]</a>, <a href="#b0030">[6]</a>. A substantial minority of infections are asymptomatic. Non-respiratory symptoms such as anosmia, diarrhoea, rash, thromboembolic disorders, myocarditis and vasculitis have also been associated with COVID-19 <a href="#b0025">[5]</a>, <a href="#b0030">[6]</a>, <a href="#b0035">[7]</a>, <a href="#b0040">[8]</a>, <a href="#b0045">[9]</a>, <a href="#b0050">[10]</a>, <a href="#b0055">[11]</a>, <a href="#b0060">[12]</a>, <a href="#b0065">[13]</a>. The median incubation period is estimated to be 5 days with a majority developing symptoms by 11.5 days <a href="#b0070">[14]</a>. COVID-19 patients have been shown to excrete viral nucleic acid at highest levels at the onset of symptoms <a href="#b0075">[15]</a>. This, and other epidemiological data <a href="#b0080">[16]</a> suggests transmissibility within an as yet undefined pre-symptomatic period <a href="#b0080">[16]</a>. Clinical deterioration is usually delayed into the second week of illness and associated with laboratory features of an immune-mediated cytokine storm causing widespread inflammation and disseminated intravascular coagulation, usually with low level viraemia <a href="#b0085">[17]</a>, <a href="#b0090">[18]</a>.</p> <p id="p0015">The case fatality rate (death amongst persons with disease) is consistently reported to be age dependent, with a higher percentage in elderly (aged &amp;gt;70 years) cases dying, although other factors are also associated with intensive care admission and mortality <a href="#b0045">[9]</a>, <a href="#b0030">[6]</a>, <a href="#b0095">[19]</a> including sex (male&amp;gt;female), hypertension, obesity and diabetes. The reported case fatality rates [CFR] have been between 0.82% and 9.64%, with variability in CFR likely due to the testing frequency and access as well as other health system capacity factors in different locations <a href="#b0100">[20]</a>. The infection fatality rate (IFT; death amongst all people infected â€" asymptomatic and not tested) is a better estimate of population mortality and is modelled to be between 0.1% to 0.41% <a href="#b0100">[20]</a>.</p> <p id="p0020">SARS-CoV-2 is one of three coronaviruses that may cause severe respiratory diseases, including fatality, in humans and have been associated with major outbreaks in the last 20 years; the other two viruses being severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). SARS-CoV and MERS-CoV (MERS-CoV). Although there were some development of vaccines against SARS and MERS, including a small number of human phase 1 clinical trials, there are no licenced vaccines for any coronavirus as yet.</p> <p id="p0025">In addition to these novel epidemic viruses with zoonotic origins, there are four other endemic human coronaviruses in circulation, HCoV2-229E, -HKU1, -NL63 and -OC43 all predominantly causing mild symptoms of the common cold <a href="#b0105">[21]</a>.</p> </div> <div class="historyofvaccinesforcoronaviruses:" title="sec"> <div class="title" tagx="title" title="title">
History of vaccines for Coronaviruses:</div> <p id="p0030">Coronaviruses have a large (30+ kb) single-stranded positive sense RNA genome encased by a helical nucleocapsid (N) and an outer envelope comprised of matrix protein (M), envelope protein (E) and spike proteins (S) <a href="#b0110">[22]</a>. The S protein, which naturally occurs in a trimeric form, contains the receptor-binding domain (RBD) responsible for binding onto the angiotensin converting enzyme 2 (ACE2) and entry into the cell (<a href="#f0005">Figure 1</a> ). In SARS-CoV, of all the structural proteins, S protein was found to elicit neutralising antibody and is a major target antigen for vaccine development <a href="#b0115">[23]</a>, <a href="#b0120">[24]</a>. </p><div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 1</span></a></div>   <p>Schematic of the structure of SARS-CoV2. <i>(Adapted from Lee, C-Y et al, Frontiers in Immunology, 2020)</i><a href="#b0500">[100]</a>.</p>   </div> <p /> <p id="p0035">There have been difficulties in the development of coronavirus vaccines historically. Coronavirus vaccines in animal models that mimic human disease have been immunogenic but generally not shown to effectively prevent acquisition of disease <a href="#b0125">[25]</a>. Further, there is a concern that vaccination, as with natural coronaviral infection, may not induce long lived immunity and re-infection may be possible <a href="#b0130">[26]</a>. In some ways more concerning has been vaccine associated disease enhancement. Previous use of coronavirus vaccines (SARS-CoV and MERS-CoV) in some animal models raised safety concerns regarding Th2 mediated immunopathology <a href="#b0135">[27]</a>. Mice vaccinated with two inactivated whole virus vaccines, a recombinant DNA spike protein vaccine or a virus-like particle vaccine developed lung pathology including eosinophilic infiltration 2 days after being challenged with SARS-CoV which were not seen in the lungs of challenged unvaccinated mice <a href="#b0140">[28]</a>. Similar lung immunopathology was observed in several other studies, particularly in aged mice compared to younger mice <a href="#b0145">[29]</a> that were challenged following vaccination <a href="#b0150">[30]</a>, <a href="#b0155">[31]</a>. Mice immunised with SARS-CoV N protein vaccine developed severe pneumonia or lung eosinophilic infiltrate upon viral challenge, whereas mice immunised with viral replicon particles expressing glycoprotein did not, suggesting that the N protein antigen may be the antigen linked to this immunopathology. Similar enhanced immunopathology has been seen in mice vaccinated with inactivated MERS-CoV vaccine when challenged with live virus <a href="#b0160">[32]</a>. Vaccine associated disease enhancement may be more of a concern with certain vaccine types. Enhanced disease caused by viral challenge has been notable following administration of inactivated measles and RSV vaccines <a href="#b0165">[33]</a>, <a href="#b0170">[34]</a>, with the possible mechanisms being a Th2 skewed response resulting from formalin inactivation as well as lack of affinity maturation of the antibodies produced <a href="#b0175">[35]</a>.</p> </div> <div class="sars-cov-2/covid-19vaccines:" title="sec"> <div class="title" tagx="title" title="title">
SARS-CoV-2/COVID-19 vaccines:</div> <div class="context:" title="sec"> <div class="title" tagx="title" title="title">
Context:</div> <p id="p0040">Developing and scaling-up mass production of a vaccine rapidly in a global pandemic setting is challenging as it requires many activities to be well-coordinated and occurring in parallel, in contrast to the usual decade long, sequential process with pre-clinical testing, phased clinical trials, planned production and distribution. These challenges result in an aggregation of invested resources and elevated financial risk <a href="#b0180">[36]</a>. In outbreaks, delay in vaccine distribution can result in considerable mortality and morbidity as illustrated by the 2013/2014 West African Ebola epidemic which killed more than 11,000 people <a href="#b0185">[37]</a> and resulted in economic and social burden costing over 53 billion dollars <a href="#b0190">[38]</a>. Tragically, a vaccine had been in development and was later shown to be effective in the prevention of Ebola and may have contributed to controlling the outbreak <a href="#b0195">[39]</a>, <a href="#b0200">[40]</a>. Unfortunately, the SARS 2003 epidemic ended before vaccine development was complete. Disappointingly, funding agencies then reallocated funds that had been committed to vaccine development, leaving manufacturers with financial loss and setting back other vaccine development programs <a href="#b0180">[36]</a>. In 2017, the Coalition of Epidemic Preparedness Innovation (CEPI) was formed to address these past failures with a mission to develop a coordinated response to emerging infectious disease threats to ensure vaccine development and early deployment in response to epidemics <a href="#b0205">[41]</a>.</p> </div> </div> <div class="diversityoftechnologyplatforms:" title="sec"> <div class="title" tagx="title" title="title">
Diversity of technology platforms:</div> <p id="p0045">One method for overcoming road blocks has been to through the use of new technology platforms to expedite vaccine development <a href="#b0210">[42]</a>. Vaccines licensed in humans have traditionally been live attenuated viruses (e.g. Measles, mumps, rubella), inactivated viruses (e.g. inactivated polio vaccine) protein or polysaccharide conjugated subunit vaccines (protein: acellular pertussis, hepatitis B; polysaccharide conjugated: pneumococcus, meningococcus), and virus-like particles. Over the last decade, a range of new technology platforms have been developed and include vaccines composed of nucleic acid (DNA and RNA) and viral vectors and recombinant proteins.</p> </div> <div class="recombinantvaccines/viralvectors:" title="sec"> <div class="title" tagx="title" title="title">
Recombinant vaccines/viral vectors:</div> <p id="p0050">Viral vector technology involves the delivery of one or more genes that encode a target antigen within an unrelated, engineered virus. The viral vector can be replication competent (live attenuated) or replication deficient. For HIV, Ebola, Zika and Chikungunya, vaccines using viral vectors including adenovirus (Ad), measles virus (MV), vesicular stomatitis virus (VSV), alphaviruses, poxviruses and herpesviruses allowing for insertion of 5 kb or more of the transgene have shown ability to stimulate cellular and humoral immunity <a href="#b0215">[43]</a>, <a href="#b0210">[42]</a>. Concerns with this platform are with the likely slower speed of vaccine manufacturing in an outbreak setting given the need for biosafety level 2 (BSL2) laboratories, and possible pre-existing immunity in vaccine recipients to viral vectors such as Ad5 and MV decreasing the effectiveness of the vaccine. Approaches such as the selection of low human prevalence adenoviral serotypes (Ad26 or Ad35) have been used to circumvent such an issue <a href="#b0215">[43]</a>, <a href="#b0210">[42]</a>. The recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) Ebola vaccine is currently the only vector-vaccine that has been licensed and available for human use, and only produced and used to a limited extent <a href="#b0220">[44]</a>, <a href="#b0225">[45]</a>, <a href="#b0230">[46]</a>.</p> <p id="p0055">A MERS-CoV vaccine (MVA-MERS-S_DF1) using modified vaccinia virus Ankara and expressing the spike (S) protein of MERS-CoV was evaluated in an open label, phase 1 trial on 26 individuals aged 18-55. It showed a favourable safety profile without any severe adverse effects but induced only a relatively limited humoral and T-cell response to the MERS CoV <a href="#b0235">[47]</a>. Reassuringly, the study showed that although vector specific neutralisation antibody was elicited, the vaccine still elicited antibody responses against the transgene following booster immunisation <a href="#b0235">[47]</a>. Results of the phase 1 clinical trial for an alternate vaccine, ChAdOx1 MERS vaccine that uses a replication deficient simian adenoviral vector expressing the spike (S) protein in 24 individuals aged 18-50 years showed that a single dose was able to elicit both humoral and cellular responses against MERS CoV. The majority of solicited and unsolicited adverse events (AEs) reported by participants were mild or moderate and all were self-limiting, and there were no serious AEs related to vaccine administration, which supports progression into phase 1b and 2 trials <a href="#b0240">[48]</a>.</p> </div> <div class="nucleicacidvaccines:" title="sec"> <div class="title" tagx="title" title="title">
Nucleic acid vaccines:</div> <p id="p0060">Nucleic acid vaccines utilize antigen-encoding plasmid DNA or RNA, messenger RNA (mRNA) or viral replicons. The nucleic acid, once taken up by a cell will initiate protein synthesis, to which a humoral and cell-mediated immune response is expected to occur, similar to natural infection. Such vaccines have been trialled for veterinary infectious diseases and demonstrated immunogenicity, for example, for foot and mouth disease, deer powassan virus and rabies virus <a href="#b0245">[49]</a>, <a href="#b0250">[50]</a>, <a href="#b0255">[51]</a>. Phase I trials in humans are underway for nucleic acid vaccines against Ebola, influenza and Zika virus <a href="#b0210">[42]</a>. The benefit of a nucleic acid platform is the ease with which it allows antigen manipulation and the speed of production, as manufacturing can be synthetic and entirely cell free so circumventing the need for BSL2 laboratories. The disadvantages are that nucleic acid, especially mRNA, are fragile and require an uninterrupted cold-chain process for transport and storage <a href="#b0260">[52]</a>. Phase I clinical trials have been conducted on SARS-CoV and MERS-CoV DNA vaccine candidates. A recombinant SARS DNA vaccine candidate coding for the SARS-CoV N protein genome, developed by the National Institute of Allergy and Infectious Diseases (NIAID) was investigated in 10 adults <a href="#b0265">[53]</a>. A MERS-CoV DNA vaccine (GLS-5300), developed by GeneOne Life Science/Inovio and coding for the full length S protein genome, had a higher number of participants (n=75) <a href="#b0270">[54]</a> Both showed acceptable safety profiles and induced humoral and cellular responses; the MERS-CoV DNA vaccine has advanced into a phase 2 clinical trial <a href="#b0275">[55]</a>. The only other SARS vaccine to have entered a Phase I trial is an inactivated vaccine (ISCV) produced by Sinovac Biotech <a href="#b0280">[56]</a>. There were no reports of human studies in which vaccinated subjects were challenged by the natural virus.</p> </div> <div class="vaccinecandidates:" title="sec"> <div class="title" tagx="title" title="title">
Vaccine Candidates:</div> <p id="p0065">As of 1<sup>st</sup> June 2020, there are currently 124 candidate vaccines that are under development for prevention of COVID-19 listed by the WHO Health Organization (WHO) landscape summary <a href="#b0285">[57]</a> of which 10 candidate vaccines specifically designed for prevention of COVID-19 (<a href="#t0005">Table 1</a> ) have entered phase 1, combined phase 1/2 or phase 2 human clinical trials in adults. Most of these trials are enrolling healthy adults (from age 18 years) only, with the upper age limit of inclusion ranging from 50 to 60 years. Two trials are enrolling young participants, one from aged â‰¥3 years and the other â‰¥6 years with no upper age limit in both. One combined phase I/II trial includes older adults (up to age 85 years), while another early phase I trial has been extended in May 2020 to include also older adults (to age 99 years) <a href="#b0290">[58]</a>, <a href="#b0295">[59]</a>. <div class="table-wrap_UNKNOWN" position="float" id="t0005"><span class="label" tagx="label" title="label">Table 1</span> </div></p><p>Candidate COVID-19 vaccines currently in phase 1 or 2 human clinical trials.</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th>Platform</th> <th>Description</th> <th>Advantages</th> <th>Disadvantages</th> </tr> </thead> <tbody> <tr> <td><b>Recombinant Viral vector</b></td> <td>Unrelated virus engineered to encode the target gene of the pathogen. Viral vectors can be replicating or non-replicating</td> <td>Induces high cellular and humoral immune responses</td> <td>Possible pre-existing immunity against vectorRisk of reversion to virulenceLimitations in scaling-up production</td> </tr> <tr> <td><i>Candidate vaccines:</i></td> <td colspan="3"><b>Ad5-CoV</b>Adenovirus Type 5 vector; antigen: Spike proteinPhase I: CanSino Biologics ChiCTR2000030906 <a href="#b0440">[88]</a>/NCT04313127 <a href="#b0445">[89]</a>Phase II: Institute of Biotechnology; Academy of Military Medical SciencesChiCTR2000031781 <a href="#b0450">[90]</a>/NCT04341389 <a href="#b0455">[91]</a>Participants: 18â€"60 years; Phase I n=108Phase II: n=508<i>Phase I: vaccine was safe and tolerable. No serious adverse effects. 63 participants (Low dose n=18 [50%); moderate dose n=18 [50%]; high dose n=27 [75%]) developed four fold rise in neutralising antibody titres by Day 28. Pre-existing immunity to Ad5 neutralising antibody titre was observed in half of the participants before vaccination. Out of these, a low proportion seroconverted</i><a href="#b0380">[76]</a>, <a href="#b0005">[1]</a><b>AZD1222 (previous known as ChAdOx1 nCoV-19)</b>Simian adenoviral vaccine vector; antigen: Spike proteinPhase I/II: University of Oxford NCT04324606 <a href="#b0460">[92]</a>Participants: 18-55 years; n= 1090</td> </tr> <tr> <td><b>Inactivated</b></td> <td>Pathogen virus inactivated by chemicals or radiation</td> <td>Easy to prepareHigh safety</td> <td>Variable efficacy</td> </tr> <tr> <td><i>Candidate vaccines:</i></td> <td colspan="3"><b>PiCoVacc</b>Phase I/II: Sinovac Biotech Co NCT04352608 <a href="#b0465">[93]</a>Participants: 18-59 years; Phase I n=144; Phase II n=600Phase I/II: Sinovac Biotech Co NCT04383574 <a href="#b0470">[94]</a>Participants: â‰¥60 years; Phase I n=72; Phase II n=350<b>Inactivated novel coronavirus vaccine</b>Phase I/II: Beijing Institute of Biological Products/SinopharmChiCTR2000032459 <a href="#b0475">[95]</a>Recruitment: Age &amp;gt;/= 3 years; Phase I n=480; Phase II n=1168<b>Inactivated novel coronavirus vaccine</b> Phase I/II: Wuhan Institute of Biological Products/SinopharmChiCTR2000031809 <a href="#b0475">[95]</a>Participants: Age &amp;gt;/= 6 years; Phase I n=288; Phase II n=1168</td> </tr> <tr> <td><b>Live attenuated</b></td> <td>Live virus whose genome(s) is mutated, inducing immune response but not disease</td> <td>Induces long-term immunity</td> <td>Expensive to produce</td> </tr> <tr> <td><i>Candidate vaccines:</i></td> <td colspan="3">Nil in clinical trials as yet</td> </tr> <tr> <td><b>Protein subunit</b></td> <td>Components of target antigen protein produced in laboratory; some vaccines may use nanoparticle technology</td> <td>High safetyScalability</td> <td>High costLower immunogenicity and may require adjuvant or repeat doses</td> </tr> <tr> <td><i>Candidate vaccines:</i></td> <td colspan="3"><b>NVX-CoV2373</b>Phase I: Novovax NCT04368988 <a href="#b0480">[96]</a>Participants: 18-59 years; n=131</td> </tr> <tr> <td><b>Virus like particle</b></td> <td>Non-infectious self- assembling viral structural proteins</td> <td>Induces strong immune response</td> <td>Limitations in manufacturing production</td> </tr> <tr> <td><i>Candidate vaccines:</i></td> <td colspan="3">Nil in clinical trial as yet</td> </tr> <tr> <td><b>mRNA</b></td> <td>mRNA encoding target antigen (may be complexed with lipid- or polymer-based nanoparticles)</td> <td>Easier to designInduces strong immune responseRapid manufacture</td> <td>Requires mRNA to be encapsulated otherwise unstable under physiological conditions</td> </tr> <tr> <td><i>Candidate vaccines:</i></td> <td colspan="3"><b>BNT162</b>Phase I/II: BioNTech/PfizerFour candidates, two candidates include a nucleoside modified mRNA, one a uridine containing mRNA and the fourth self- amplifying mRNA. Each combined with a lipid nanoparticle formulation.Germany 2020-001038-36 <a href="#b0485">[97]</a>Participants: 18â€"55 years; n=196USA NCT04368728 <a href="#b0480">[96]</a>Participants: 18â€"85 years; n=7600<b>mRNA-1273Lipid nano-particle (LNP)-encapsulated mRNA vaccine;Coding antigen: full length S-protein</b>Phase I/II: Moderna/National Institute of Allergy and infectious diseasesNCT04283461 <a href="#b0295">[59]</a>Participants: 18-55 years, extended to 99 years n=155<i>Interim Phase 1 Data: 15 participants seroconverted by day 15; 8 participants: all developed neutralizing antibodies</i><a href="#b0385">[77]</a></td> </tr> <tr> <td><b>DNA</b></td> <td>DNA that encodes the target antigen</td> <td>Easier to designRapid manufacture</td> <td>May require a special approach to administer the vaccine (e.g. electroporation device)May requires adjuvant Uncertainty of safety issues</td> </tr> <tr> <td /> <td colspan="3"><b>INO-4800</b>Phase I: Inovio Pharmaceuticals NCT04336410 <a href="#b0490">[98]</a>Participants : 18-50 years n=40<b>Plasmid DNA oral vaccine (bacTRL-IL-Spike-1)</b>Phase 1: Symvivo NCT04334980 <a href="#b0495">[99]</a>Participants: 19=55 years; n= 84</td> </tr> </tbody> </table>  <p /> </div> <div class="re-purposedvaccinesofforcovid-19orofftargeteffectsofothervaccines:" title="sec"> <div class="title" tagx="title" title="title">
Re-purposed vaccines of for COVID-19 or off target effects of other vaccines:</div> <p id="p0070">Licensed vaccines such as BCG and oral polio vaccine have been shown to have nonspecific, modulatory effects on the immune system and provide protection against other infectious diseases <a href="#b0300">[60]</a>, <a href="#b0305">[61]</a>, <a href="#b0310">[62]</a>, <a href="#b0315">[63]</a>, <a href="#b0320">[64]</a>. This has led to the suggestion that these vaccines may have an effect in the prevention of COVID-19 <a href="#b0325">[65]</a>. Three multi-centred randomised controlled trials on BCG vaccine administration are underway in health care workers in Australia <a href="#b0330">[66]</a>, Netherlands <a href="#b0335">[67]</a> and South Africa <a href="#b0340">[68]</a>. A measles vaccine trial to prevent COVID-19 in health care workers in Egypt has been registered <a href="#b0290">[58]</a> and oral polio vaccines are being considered in the United States of America <a href="#b0345">[69]</a>.</p> </div> <div class="discussion:" title="sec"> <div class="title" tagx="title" title="title">
Discussion:</div> <p id="p0075">Even if sustained immunity is attained after infection by SARS-CoV2, estimates are that 60-70% of a population would need to be immune to achieve herd immunity against SARS-CoV2 <a href="#b0350">[70]</a>. The safest and most controlled way for effective and sustainable prevention of COVID-19 in a population is to have an efficacious and safe vaccine and the majority of the population successfully vaccinated. In addition, the vaccine should also be readily mass-produced inexpensively, and be easily transportable with minimal cold chain requirements to have global utility. Immunity after primary COVID-19 infection seems to protect against re-infection in primate models and is likely to occur in humans <a href="#b0355">[71]</a>; whether this can be mimicked in vaccines and for how long immunity may last is still uncertain. Following SARS-CoV infection, IgG and Neutralising Ab was detectable for 1 to 3 years following infection which suggests that vaccine-induced protection is unlikely to be long-lasting and may require re-immunization <a href="#b0360">[72]</a>, <a href="#b0365">[73]</a>, <a href="#b0370">[74]</a>, <a href="#b0375">[75]</a>.</p> <p id="p0080">The rapid progression of new vaccine candidates against SARS-CoV-2 into pre-clinical and clinical studies is encouraging. Several phase 1 trial results have recently been released. Ad5-CoV vaccine, conducted in 108 participants showed reasonable safety or tolerability profile and has now progressed to phase II. Humoral and cell mediated responses were seen in participants, albeit less in those with pre-existing Ad5 vector immunity <a href="#b0380">[76]</a>. Interim phase 1 data, released on May 18 on mRNA-1273 demonstrated seroconversion and development of neutralizing antibodies in 8 individuals <a href="#b0385">[77]</a>. It is an open question of whether these candidates will display the necessary efficacy and safety profile in humans to progress further into phase 3 trials and subsequently licensure and use to control COVID-19 transmission. In a review of 11 epidemic infectious diseases, only 1 out of 11 (21 preclinical vaccine candidates) have been shown to go through to end of phase 2a trials, at the estimated cost of USD $319-469 million (range $137 million to $1.1 billion) <a href="#b0390">[78]</a>. In the current climate, some vaccine developers are have shown willingness to start or progress later phase trial preparations even before definitive results of earlier phase trials are available <a href="#b0395">[79]</a>.</p> <p id="p0085">There have been international collaborative efforts to expedite vaccine development and production. The prior establishment of CEPI has been an integral existing platform that has supported the rapid development of COVID-19 vaccines without having to establish new mechanisms with attendant costs. CEPI is supporting the nine COVID-19 vaccine candidates briefly presented here. Since its formation it has established measures to finance early development of vaccines, up to phase 3 clinical trials. However, it does not have a role in the manufacturing or deployment of vaccines and a consortium of public and philanthropic funders will be required for complete preparedness for vaccine manufacture and delivery.</p> <p id="p0090">In addition to CEPI, the WHO and the U.S. National Institutes of Health (NIH) are contributing to global collaborative efforts to accelerate vaccine development. The WHO Solidarity Trial for vaccines is a large, multi-site individually randomised controlled clinical trial to allow evaluation of the benefits and risks of each COVID-19 candidate vaccines within 3â€"6 months <a href="#b0400">[80]</a>. Further, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), an international public-private partnership, has been established to co-ordinate and speed up the response to the COVID-19 pandemic. Government organisations (in the US and one in Europe), international biopharmaceutical companies and a non-profit organisation are all involved in advancing vaccine development <a href="#b0405">[81]</a>.</p> <p id="p0095">Vaccine efficacy in under-represented and vulnerable populations also remains an issue. A majority of vaccine trials have focused on healthy people between the ages of 18-65 years, excluding the elderly, pregnant women and children. Given the disproportionate mortality rate in people over the age of 60, the elderly need to be considered in vaccine trials to ensure safety, immunogenicity and efficacy data is collected and are prioritised to receive COVID-19 vaccines in outbreak situations. Pregnancy has not been shown to be a risk factor for disease severity and the disease burden is low in children. However, much is still unknown, especially the role of inducing an adaptive auto-inflammatory response such as Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS). There is an urgent need for a better understanding of the immunopathogenesis of COVID-19 to give guidance to the immunological assessment of vaccine responses.</p> <p id="p0100">There has never been a more rapid pace to vaccine development. The pandemic situation has been a challenge and a trigger to reconsidering the usual approaches to regulatory assessment and licensing processes. Vaccine companies are showing willingness to commit to scaled-up production prior to definitive phase 3 trial results <a href="#b0395">[79]</a>. The implementation of high quality, aligned surveillance for COVID-19 across multiple regions concurrently with vaccine deployment is critical both for evaluating the real-world effectiveness of a new vaccine against SARS-CoV-2, but also for monitoring its safety in so-call â€˜post-marketingâ€™ surveillance. The association of rotavirus vaccines with intussusception in children was only detected following licensure and deployment of these vaccines <a href="#b0410">[82]</a>, <a href="#b0415">[83]</a>., the experience of the Philippines with a novel Dengue vaccine should also promote a degree of caution with respect to vaccine safety during their population usage even if they appear safe in phase 1, 2 and 3 studies. <a href="#b0420">[84]</a>, <a href="#b0425">[85]</a> There will be considerable uncertainties regarding the safety of vaccines for COVID-19 given the new vaccine platforms used without prior licensed examples, deployment to population subgroups not included in trials of that particular candidate), additional uncertainty arising from novel adjuvants in quite a number of candidates.</p> <p id="p0105">As we have alluded to, the development of a vaccine that shows efficacy in clinical trials is only the beginning of a process to manufacture, deploy and monitor the effectiveness of a new vaccine. The challenges ahead are numerous. As an example, in 2016 as part of the Global Poliovirus Eradication Initiative (GPEI), 155 countries were planned to synchronously shift from trivalent oral polio vaccine (tOPV) to bivalent vaccine (bOPV) <a href="#b0430">[86]</a>. This switch was to be coordinated with concurrent inclusion of at least 1 dose of inactivated polio vaccine (IPV) into routine immunization schedules in 126 OPV using countries. Significant difficulties have been encountered with vaccine manufacturing and supply chains resulting in interruptions and delays in multiple countries <a href="#b0435">[87]</a>. This experience will certainly inform and improve a potential global COVID-19 vaccine deployment, but should influence a level of caution with respect to our expectations even were an effective vaccine developed.</p> <p id="p0110">Despite efforts in fast tracking vaccine development, completion dates for early clinical trials are estimated to be late 2020 to mid-2021 and it may still take longer before a vaccine is licensed for use globally, although the pandemic has triggered reconsideration of the usual approaches to regulatory assessment and licensing. This emphasises the need for proven public health strategies such as physical distancing, early detection, self-isolation and outbreak control remain as important mitigation tools.</p> </div> <div class="educationalaims:" title="sec"> <div class="title" tagx="title" title="title">
Educational Aims:</div> <p id="p0115">The reader will be able to: </p><ul> <li><span class="label" tagx="label" title="label">â€¢</span><p id="p0120">Understand of the types of vaccine and vaccine platforms being developed for SARS-CoV-2.</p> </li> <li><span class="label" tagx="label" title="label">â€¢</span><p id="p0125">Develop knowledge regarding the concerns around coronavirus vaccine development.</p> </li> <li><span class="label" tagx="label" title="label">â€¢</span><p id="p0130">Appreciated the issues of rapid vaccine development in outbreak settings.</p> </li> </ul> <p /> </div> <div class="futureresearchdirections:" title="sec"> <div class="title" tagx="title" title="title">
Future research directions:</div> <p id="p0135"> </p><ul> <li><span class="label" tagx="label" title="label">â€¢</span><p id="p0140">Ongoing progress of candidate vaccines through preclinical and clinical studies.</p> </li> <li><span class="label" tagx="label" title="label">â€¢</span><p id="p0145">Ongoing detailed characterisation of the immunopathogenesis of COVID-19.</p> </li> <li><span class="label" tagx="label" title="label">â€¢</span><p id="p0150">Implementation of large scale post marketing surveillance systems to monitor SARS-CoV2 vaccine safety.</p> </li> </ul> <p /> </div> </div> <div class="back" title="back"> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References:</div> <li tag="ref"><a name="b0005" /><span class="label" tagx="label" title="label">1</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhu</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A novel coronavirus from patients with pneumonia in China, 2019</span><span class="source" tagx="source" title="source">New England Journal of Medicine</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0010" /><span class="label" tagx="label" title="label">2</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wu</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A new coronavirus associated with human respiratory disease in China</span><span class="source" tagx="source" title="source">Nature</span><span class="volume" tagx="volume" title="volume">579</span><span class="issue" tagx="issue" title="issue">7798</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">265</span><span class="lpage" tagx="lpage" title="lpage">269</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32015508">32015508</a></span></span></li> <li tag="ref"><a name="b0015" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Centre for Systems Science and Engineering. COVID-19 Dashboard. 2020 [cited 2020 June 3, 2020]; Available from: https://coronavirus.jhu.edu/map.html.</span></li> <li tag="ref"><a name="b0020" /><span class="label" tagx="label" title="label">4</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guan</span><span class="given-names" tagx="given-names" title="given-names">W.-J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Clinical characteristics of coronavirus disease 2019 in China</span><span class="source" tagx="source" title="source">New England journal of medicine</span><span class="volume" tagx="volume" title="volume">382</span><span class="issue" tagx="issue" title="issue">18</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1708</span><span class="lpage" tagx="lpage" title="lpage">1720</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32109013">32109013</a></span></span></li> <li tag="ref"><a name="b0025" /><span class="label" tagx="label" title="label">5</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</span><span class="source" tagx="source" title="source">The Lancet</span><span class="volume" tagx="volume" title="volume">395</span><span class="issue" tagx="issue" title="issue">10223</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">507</span><span class="lpage" tagx="lpage" title="lpage">513</span></span></li> <li tag="ref"><a name="b0030" /><span class="label" tagx="label" title="label">6</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bhatraju</span><span class="given-names" tagx="given-names" title="given-names">P.K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Covid-19 in critically ill patients in the Seattle regionâ€"case series</span><span class="source" tagx="source" title="source">New England Journal of Medicine</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0035" /><span class="label" tagx="label" title="label">7</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusâ€"infected pneumonia in Wuhan</span><span class="source" tagx="source" title="source"><i>China.</i> Jama</span><span class="volume" tagx="volume" title="volume">323</span><span class="issue" tagx="issue" title="issue">11</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1061</span><span class="lpage" tagx="lpage" title="lpage">1069</span></span></li> <li tag="ref"><a name="b0040" /><span class="label" tagx="label" title="label">8</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pan</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study</span><span class="source" tagx="source" title="source">The American journal of gastroenterology</span><span class="volume" tagx="volume" title="volume">115</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0045" /><span class="label" tagx="label" title="label">9</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Huang</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Clinical features of patients infected with 2019 novel coronavirus in Wuhan</span><span class="source" tagx="source" title="source"><i>China.</i> The lancet</span><span class="volume" tagx="volume" title="volume">395</span><span class="issue" tagx="issue" title="issue">10223</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">497</span><span class="lpage" tagx="lpage" title="lpage">506</span></span></li> <li tag="ref"><a name="b0050" /><span class="label" tagx="label" title="label">10</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Giacomelli</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study</span><span class="source" tagx="source" title="source">Clinical Infectious Diseases</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0055" /><span class="label" tagx="label" title="label">11</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhou</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A pneumonia outbreak associated with a new coronavirus of probable bat origin</span><span class="source" tagx="source" title="source">Nature</span><span class="volume" tagx="volume" title="volume">579</span><span class="issue" tagx="issue" title="issue">7798</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">270</span><span class="lpage" tagx="lpage" title="lpage">273</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32015507">32015507</a></span></span></li> <li tag="ref"><a name="b0060" /><span class="label" tagx="label" title="label">12</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Song</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span></span><span class="mixed-article-title" title="mixed-article-title">SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19</span><span class="source" tagx="source" title="source">Gut</span><span class="volume" tagx="volume" title="volume">69</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1143</span><span class="lpage" tagx="lpage" title="lpage">1144</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32139552">32139552</a></span></span></li> <li tag="ref"><a name="b0065" /><span class="label" tagx="label" title="label">13</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Recalcati</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cutaneous manifestations in COVID-19: a first perspective</span><span class="source" tagx="source" title="source">Journal of the European Academy of Dermatology and Venereology</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0070" /><span class="label" tagx="label" title="label">14</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lauer</span><span class="given-names" tagx="given-names" title="given-names">S.A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application</span><span class="source" tagx="source" title="source">Annals of internal medicine</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0075" /><span class="label" tagx="label" title="label">15</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zou</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients</span><span class="source" tagx="source" title="source">New England Journal of Medicine</span><span class="volume" tagx="volume" title="volume">382</span><span class="issue" tagx="issue" title="issue">12</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1177</span><span class="lpage" tagx="lpage" title="lpage">1179</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32074444">32074444</a></span></span></li> <li tag="ref"><a name="b0080" /><span class="label" tagx="label" title="label">16</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">He</span><span class="given-names" tagx="given-names" title="given-names">X.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Temporal dynamics in viral shedding and transmissibility of COVID-19</span><span class="source" tagx="source" title="source">Nature medicine</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1</span><span class="lpage" tagx="lpage" title="lpage">4</span></span></li> <li tag="ref"><a name="b0085" /><span class="label" tagx="label" title="label">17</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhou</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</span><span class="source" tagx="source" title="source">The lancet</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0090" /><span class="label" tagx="label" title="label">18</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tang</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</span><span class="source" tagx="source" title="source">Journal of Thrombosis and Haemostasis</span><span class="volume" tagx="volume" title="volume">18</span><span class="issue" tagx="issue" title="issue">4</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">844</span><span class="lpage" tagx="lpage" title="lpage">847</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32073213">32073213</a></span></span></li> <li tag="ref"><a name="b0095" /><span class="label" tagx="label" title="label">19</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guan</span><span class="given-names" tagx="given-names" title="given-names">W.-J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis</span><span class="source" tagx="source" title="source">European Respiratory Journal</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">2000547</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32217650">32217650</a></span></span></li> <li tag="ref"><a name="b0100" /><span class="label" tagx="label" title="label">20</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Oke, J. and C. Heneghan. Global COVID-19 Case Fatality Rates. 2002 19 May 2020 [cited 2020 24 May 2020]; Available from: https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/.</span></li> <li tag="ref"><a name="b0105" /><span class="label" tagx="label" title="label">21</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zimmermann</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Curtis</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children</span><span class="source" tagx="source" title="source">The Pediatric Infectious Disease Journal</span><span class="volume" tagx="volume" title="volume">39</span><span class="issue" tagx="issue" title="issue">5</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">355</span><span class="lpage" tagx="lpage" title="lpage">368</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32310621">32310621</a></span></span></li> <li tag="ref"><a name="b0110" /><span class="label" tagx="label" title="label">22</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Boopathi</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Poma</span><span class="given-names" tagx="given-names" title="given-names">A.B.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kolandaivel</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Novel coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment</span><span class="source" tagx="source" title="source">Journal of Biomolecular Structure and Dynamics</span><span class="volume" tagx="volume" title="volume">2020</span><span class="year" tagx="year" title="year">2019</span><span class="fpage" tagx="fpage" title="fpage">1</span><span class="lpage" tagx="lpage" title="lpage">10</span></span></li> <li tag="ref"><a name="b0115" /><span class="label" tagx="label" title="label">23</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Buchholz</span><span class="given-names" tagx="given-names" title="given-names">U.J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity</span><span class="source" tagx="source" title="source">Proc Natl Acad Sci U S A</span><span class="volume" tagx="volume" title="volume">101</span><span class="issue" tagx="issue" title="issue">26</span><span class="year" tagx="year" title="year">2004</span><span class="fpage" tagx="fpage" title="fpage">9804</span><span class="lpage" tagx="lpage" title="lpage">9809</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15210961">15210961</a></span></span></li> <li tag="ref"><a name="b0120" /><span class="label" tagx="label" title="label">24</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Walls</span><span class="given-names" tagx="given-names" title="given-names">A.C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</span><span class="source" tagx="source" title="source">Cell</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0125" /><span class="label" tagx="label" title="label">25</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Roper</span><span class="given-names" tagx="given-names" title="given-names">R.L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rehm</span><span class="given-names" tagx="given-names" title="given-names">K.E.</span></span></span><span class="mixed-article-title" title="mixed-article-title">SARS vaccines: where are we?</span><span class="source" tagx="source" title="source">Expert Rev Vaccines</span><span class="volume" tagx="volume" title="volume">8</span><span class="issue" tagx="issue" title="issue">7</span><span class="year" tagx="year" title="year">2009</span><span class="fpage" tagx="fpage" title="fpage">887</span><span class="lpage" tagx="lpage" title="lpage">898</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19538115">19538115</a></span></span></li> <li tag="ref"><a name="b0130" /><span class="label" tagx="label" title="label">26</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Edridge, A., et al., Human coronavirus reinfection dynamics: lessons for SARS-CoV-2. 2020.</span></li> <li tag="ref"><a name="b0135" /><span class="label" tagx="label" title="label">27</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Graham</span><span class="given-names" tagx="given-names" title="given-names">R.L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Donaldson</span><span class="given-names" tagx="given-names" title="given-names">E.F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baric</span><span class="given-names" tagx="given-names" title="given-names">R.S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A decade after SARS: strategies for controlling emerging coronaviruses</span><span class="source" tagx="source" title="source">Nature reviews. Microbiology</span><span class="volume" tagx="volume" title="volume">11</span><span class="issue" tagx="issue" title="issue">12</span><span class="year" tagx="year" title="year">2013</span><span class="fpage" tagx="fpage" title="fpage">836</span><span class="lpage" tagx="lpage" title="lpage">848</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24217413">24217413</a></span></span></li> <li tag="ref"><a name="b0140" /><span class="label" tagx="label" title="label">28</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tseng</span><span class="given-names" tagx="given-names" title="given-names">C.-T.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</span><span class="source" tagx="source" title="source">PloS one</span><span class="year" tagx="year" title="year">2012</span><span class="fpage" tagx="fpage" title="fpage">7(4)</span></span></li> <li tag="ref"><a name="b0145" /><span class="label" tagx="label" title="label">29</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Deming, D., et al., Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS medicine, 2006. 3(12): p. e525-e525.</span></li> <li tag="ref"><a name="b0150" /><span class="label" tagx="label" title="label">30</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bolles</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge</span><span class="source" tagx="source" title="source">Journal of virology</span><span class="volume" tagx="volume" title="volume">85</span><span class="issue" tagx="issue" title="issue">23</span><span class="year" tagx="year" title="year">2011</span><span class="fpage" tagx="fpage" title="fpage">12201</span><span class="lpage" tagx="lpage" title="lpage">12215</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21937658">21937658</a></span></span></li> <li tag="ref"><a name="b0155" /><span class="label" tagx="label" title="label">31</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yasui</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV</span><span class="source" tagx="source" title="source">The Journal of Immunology</span><span class="volume" tagx="volume" title="volume">181</span><span class="issue" tagx="issue" title="issue">9</span><span class="year" tagx="year" title="year">2008</span><span class="fpage" tagx="fpage" title="fpage">6337</span><span class="lpage" tagx="lpage" title="lpage">6348</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18941225">18941225</a></span></span></li> <li tag="ref"><a name="b0160" /><span class="label" tagx="label" title="label">32</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Agrawal</span><span class="given-names" tagx="given-names" title="given-names">A.S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus</span><span class="source" tagx="source" title="source">Human Vaccines &amp;amp; Immunotherapeutics</span><span class="volume" tagx="volume" title="volume">12</span><span class="issue" tagx="issue" title="issue">9</span><span class="year" tagx="year" title="year">2016</span><span class="fpage" tagx="fpage" title="fpage">2351</span><span class="lpage" tagx="lpage" title="lpage">2356</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27269431">27269431</a></span></span></li> <li tag="ref"><a name="b0165" /><span class="label" tagx="label" title="label">33</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chin</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population</span><span class="source" tagx="source" title="source">Am J Epidemiol</span><span class="volume" tagx="volume" title="volume">89</span><span class="issue" tagx="issue" title="issue">4</span><span class="year" tagx="year" title="year">1969</span><span class="fpage" tagx="fpage" title="fpage">449</span><span class="lpage" tagx="lpage" title="lpage">463</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4305200">4305200</a></span></span></li> <li tag="ref"><a name="b0170" /><span class="label" tagx="label" title="label">34</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">H.W.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine</span><span class="source" tagx="source" title="source">Am J Epidemiol</span><span class="volume" tagx="volume" title="volume">89</span><span class="issue" tagx="issue" title="issue">4</span><span class="year" tagx="year" title="year">1969</span><span class="fpage" tagx="fpage" title="fpage">422</span><span class="lpage" tagx="lpage" title="lpage">434</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4305198">4305198</a></span></span></li> <li tag="ref"><a name="b0175" /><span class="label" tagx="label" title="label">35</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Delgado</span><span class="given-names" tagx="given-names" title="given-names">M.F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease</span><span class="source" tagx="source" title="source">Nature medicine</span><span class="volume" tagx="volume" title="volume">15</span><span class="issue" tagx="issue" title="issue">1</span><span class="year" tagx="year" title="year">2009</span><span class="fpage" tagx="fpage" title="fpage">34</span><span class="lpage" tagx="lpage" title="lpage">41</span></span></li> <li tag="ref"><a name="b0180" /><span class="label" tagx="label" title="label">36</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lurie</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Developing Covid-19 Vaccines at Pandemic Speed</span><span class="source" tagx="source" title="source">New England Journal of Medicine</span><span class="volume" tagx="volume" title="volume">382</span><span class="issue" tagx="issue" title="issue">21</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1969</span><span class="lpage" tagx="lpage" title="lpage">1973</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32227757">32227757</a></span></span></li> <li tag="ref"><a name="b0185" /><span class="label" tagx="label" title="label">37</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">WHO Ebola Response Team</span></span></span><span class="mixed-article-title" title="mixed-article-title">After Ebola in West Africa â€" Unpredictable Risks, Preventable Epidemics</span><span class="source" tagx="source" title="source">New England Journal of Medicine</span><span class="volume" tagx="volume" title="volume">375</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2016</span><span class="fpage" tagx="fpage" title="fpage">587</span><span class="lpage" tagx="lpage" title="lpage">596</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27509108">27509108</a></span></span></li> <li tag="ref"><a name="b0190" /><span class="label" tagx="label" title="label">38</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Huber, C., L. Finelli, and W. Stevens, The Economic and Social Burden of the 2014 Ebola Outbreak in West Africa. The Journal of Infectious Diseases, 2018. 218(Supplement_5): p. S698-S704.</span></li> <li tag="ref"><a name="b0195" /><span class="label" tagx="label" title="label">39</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jones</span><span class="given-names" tagx="given-names" title="given-names">S.M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses</span><span class="source" tagx="source" title="source">Nature Medicine</span><span class="volume" tagx="volume" title="volume">11</span><span class="issue" tagx="issue" title="issue">7</span><span class="year" tagx="year" title="year">2005</span><span class="fpage" tagx="fpage" title="fpage">786</span><span class="lpage" tagx="lpage" title="lpage">790</span></span></li> <li tag="ref"><a name="b0200" /><span class="label" tagx="label" title="label">40</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Henao-Restrepo</span><span class="given-names" tagx="given-names" title="given-names">A.M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ã‡a Suffit!)</span><span class="source" tagx="source" title="source">The Lancet</span><span class="volume" tagx="volume" title="volume">389</span><span class="issue" tagx="issue" title="issue">10068</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">505</span><span class="lpage" tagx="lpage" title="lpage">518</span></span></li> <li tag="ref"><a name="b0205" /><span class="label" tagx="label" title="label">41</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brende</span><span class="given-names" tagx="given-names" title="given-names">B.</span></span></span><span class="mixed-article-title" title="mixed-article-title">CEPIâ€"a new global R&amp;amp;D organisation for epidemic preparedness and response</span><span class="source" tagx="source" title="source">The Lancet</span><span class="volume" tagx="volume" title="volume">389</span><span class="issue" tagx="issue" title="issue">10066</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">233</span><span class="lpage" tagx="lpage" title="lpage">235</span></span></li> <li tag="ref"><a name="b0210" /><span class="label" tagx="label" title="label">42</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rauch</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">New vaccine technologies to combat outbreak situations</span><span class="source" tagx="source" title="source">Frontiers in immunology</span><span class="volume" tagx="volume" title="volume">9</span><span class="year" tagx="year" title="year">2018</span><span class="fpage" tagx="fpage" title="fpage">1963</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30283434">30283434</a></span></span></li> <li tag="ref"><a name="b0215" /><span class="label" tagx="label" title="label">43</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Robert-Guroff</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Replicating and non-replicating viral vectors for vaccine development</span><span class="source" tagx="source" title="source">Current opinion in biotechnology</span><span class="volume" tagx="volume" title="volume">18</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2007</span><span class="fpage" tagx="fpage" title="fpage">546</span><span class="lpage" tagx="lpage" title="lpage">556</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18063357">18063357</a></span></span></li> <li tag="ref"><a name="b0220" /><span class="label" tagx="label" title="label">44</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Regules</span><span class="given-names" tagx="given-names" title="given-names">J.A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A Recombinant Vesicular Stomatitis Virus Ebola Vaccine</span><span class="source" tagx="source" title="source">N Engl J Med</span><span class="volume" tagx="volume" title="volume">376</span><span class="issue" tagx="issue" title="issue">4</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">330</span><span class="lpage" tagx="lpage" title="lpage">341</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25830322">25830322</a></span></span></li> <li tag="ref"><a name="b0225" /><span class="label" tagx="label" title="label">45</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kennedy</span><span class="given-names" tagx="given-names" title="given-names">S.B.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia</span><span class="source" tagx="source" title="source">New England Journal of Medicine</span><span class="volume" tagx="volume" title="volume">377</span><span class="issue" tagx="issue" title="issue">15</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">1438</span><span class="lpage" tagx="lpage" title="lpage">1447</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29020589">29020589</a></span></span></li> <li tag="ref"><a name="b0230" /><span class="label" tagx="label" title="label">46</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">World Health Organization</span></span></span><span class="chapter-title" tagx="chapter-title" title="chapter-title">Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response</span><span class="year" tagx="year" title="year">2019</span><span class="publisher-name" tagx="publisher-name" title="publisher-name">The Organization</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Geneva</span></span></li> <li tag="ref"><a name="b0235" /><span class="label" tagx="label" title="label">47</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koch</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial</span><span class="source" tagx="source" title="source">The Lancet Infectious Diseases</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0240" /><span class="label" tagx="label" title="label">48</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Folegatti</span><span class="given-names" tagx="given-names" title="given-names">P.M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial</span><span class="source" tagx="source" title="source">The Lancet Infectious Diseases</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0245" /><span class="label" tagx="label" title="label">49</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pulido</span><span class="given-names" tagx="given-names" title="given-names">M.R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">RNA immunization can protect mice against foot-and-mouth disease virus</span><span class="source" tagx="source" title="source">Antiviral research</span><span class="volume" tagx="volume" title="volume">85</span><span class="issue" tagx="issue" title="issue">3</span><span class="year" tagx="year" title="year">2010</span><span class="fpage" tagx="fpage" title="fpage">556</span><span class="lpage" tagx="lpage" title="lpage">558</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20005905">20005905</a></span></span></li> <li tag="ref"><a name="b0250" /><span class="label" tagx="label" title="label">50</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">VanBlargan, L.A., et al., An mRNA vaccine protects mice against multiple tick-transmitted flavivirus infections. Cell reports, 2018. 25(12): p. 3382-3392. e3.</span></li> <li tag="ref"><a name="b0255" /><span class="label" tagx="label" title="label">51</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Saxena</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Induction of immune responses and protection in mice against rabies using a self-replicating RNA vaccine encoding rabies virus glycoprotein</span><span class="source" tagx="source" title="source">Veterinary microbiology</span><span class="volume" tagx="volume" title="volume">136</span><span class="issue" tagx="issue" title="issue">1â€"2</span><span class="year" tagx="year" title="year">2009</span><span class="fpage" tagx="fpage" title="fpage">36</span><span class="lpage" tagx="lpage" title="lpage">44</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19081687">19081687</a></span></span></li> <li tag="ref"><a name="b0260" /><span class="label" tagx="label" title="label">52</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Zhang, C., et al., Advances in mRNA Vaccines for Infectious Diseases. Frontiers in Immunology, 2019. 10(594).</span></li> <li tag="ref"><a name="b0265" /><span class="label" tagx="label" title="label">53</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Martin</span><span class="given-names" tagx="given-names" title="given-names">J.E.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial</span><span class="source" tagx="source" title="source">Vaccine</span><span class="volume" tagx="volume" title="volume">26</span><span class="issue" tagx="issue" title="issue">50</span><span class="year" tagx="year" title="year">2008</span><span class="fpage" tagx="fpage" title="fpage">6338</span><span class="lpage" tagx="lpage" title="lpage">6343</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18824060">18824060</a></span></span></li> <li tag="ref"><a name="b0270" /><span class="label" tagx="label" title="label">54</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Modjarrad</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial</span><span class="source" tagx="source" title="source">The Lancet Infectious Diseases</span><span class="volume" tagx="volume" title="volume">19</span><span class="issue" tagx="issue" title="issue">9</span><span class="year" tagx="year" title="year">2019</span><span class="fpage" tagx="fpage" title="fpage">1013</span><span class="lpage" tagx="lpage" title="lpage">1022</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31351922">31351922</a></span></span></li> <li tag="ref"><a name="b0275" /><span class="label" tagx="label" title="label">55</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT03721718. Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers 2020 [cited 2020 25 May 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT03721718.</span></li> <li tag="ref"><a name="b0280" /><span class="label" tagx="label" title="label">56</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lin</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine</span><span class="source" tagx="source" title="source">Antiviral therapy</span><span class="volume" tagx="volume" title="volume">12</span><span class="issue" tagx="issue" title="issue">7</span><span class="year" tagx="year" title="year">2007</span><span class="fpage" tagx="fpage" title="fpage">1107</span><span class="lpage" tagx="lpage" title="lpage">1113</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18018769">18018769</a></span></span></li> <li tag="ref"><a name="b0285" /><span class="label" tagx="label" title="label">57</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">World Health Organization</span></span></span><span class="mixed-article-title" title="mixed-article-title">DRAFT landscape of COVID-19 candidate vaccines</span><span class="source" tagx="source" title="source">World</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0290" /><span class="label" tagx="label" title="label">58</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT04357028. Measles Vaccine in HCW (MV-COVID19) 2020; Available from: https://clinicaltrials.gov/ct2/show/NCT04357028.</span></li> <li tag="ref"><a name="b0295" /><span class="label" tagx="label" title="label">59</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT04283461. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) 2020 May 4, 2020 [cited 2020 May 25, 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04283461.</span></li> <li tag="ref"><a name="b0300" /><span class="label" tagx="label" title="label">60</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Goodridge</span><span class="given-names" tagx="given-names" title="given-names">H.S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Harnessing the beneficial heterologous effects of vaccination</span><span class="source" tagx="source" title="source">Nature Reviews Immunology</span><span class="volume" tagx="volume" title="volume">16</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2016</span><span class="fpage" tagx="fpage" title="fpage">392</span><span class="lpage" tagx="lpage" title="lpage">400</span></span></li> <li tag="ref"><a name="b0305" /><span class="label" tagx="label" title="label">61</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pollard</span><span class="given-names" tagx="given-names" title="given-names">A.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Finn</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Curtis</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Non-specific effects of vaccines: plausible and potentially important, but implications uncertain</span><span class="source" tagx="source" title="source">Archives of Disease in Childhood</span><span class="volume" tagx="volume" title="volume">102</span><span class="issue" tagx="issue" title="issue">11</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">1077</span><span class="lpage" tagx="lpage" title="lpage">1081</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28501809">28501809</a></span></span></li> <li tag="ref"><a name="b0310" /><span class="label" tagx="label" title="label">62</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Biering-SÃ¸rensen</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Early BCG-Denmark and neonatal mortality among infants weighing&amp;lt; 2500 g: a randomized controlled trial</span><span class="source" tagx="source" title="source">Clinical Infectious Diseases</span><span class="volume" tagx="volume" title="volume">65</span><span class="issue" tagx="issue" title="issue">7</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">1183</span><span class="lpage" tagx="lpage" title="lpage">1190</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29579158">29579158</a></span></span></li> <li tag="ref"><a name="b0315" /><span class="label" tagx="label" title="label">63</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Upfill-Brown</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Nonspecific Effects of Oral Polio Vaccine on Diarrheal Burden and Etiology Among Bangladeshi Infants</span><span class="source" tagx="source" title="source">Clin Infect Dis</span><span class="volume" tagx="volume" title="volume">65</span><span class="issue" tagx="issue" title="issue">3</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">414</span><span class="lpage" tagx="lpage" title="lpage">419</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28444240">28444240</a></span></span></li> <li tag="ref"><a name="b0320" /><span class="label" tagx="label" title="label">64</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aaby</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries</span><span class="source" tagx="source" title="source">BMJ</span><span class="volume" tagx="volume" title="volume">311</span><span class="issue" tagx="issue" title="issue">7003</span><span class="year" tagx="year" title="year">1995</span><span class="fpage" tagx="fpage" title="fpage">481</span><span class="lpage" tagx="lpage" title="lpage">485</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7647643">7647643</a></span></span></li> <li tag="ref"><a name="b0325" /><span class="label" tagx="label" title="label">65</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Curtis</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Considering BCG vaccination to reduce the impact of COVID-19</span><span class="source" tagx="source" title="source">The Lancet</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0330" /><span class="label" tagx="label" title="label">66</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT04327206. BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE) 2020; Available from: https://clinicaltrials.gov/ct2/show/NCT04327206.</span></li> <li tag="ref"><a name="b0335" /><span class="label" tagx="label" title="label">67</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT04328441. Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA); Available from: https://clinicaltrials.gov/ct2/show/NCT04328441.</span></li> <li tag="ref"><a name="b0340" /><span class="label" tagx="label" title="label">68</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT04379336. BCG Vaccination for Healthcare Workers in COVID-19 Pandemic 2020; Available from: https://clinicaltrials.gov/ct2/show/NCT04379336.</span></li> <li tag="ref"><a name="b0345" /><span class="label" tagx="label" title="label">69</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Global Polio Eradication Initiative. The use of oral polio vaccine (OPV) to prevent SARS-CoV2. 2020 [cited 2020 24 May 2020]; Available from: http://polioeradication.org/wp-content/uploads/2020/03/Use-of-OPV-and-COVID-20200421.pdf.</span></li> <li tag="ref"><a name="b0350" /><span class="label" tagx="label" title="label">70</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Randolph</span><span class="given-names" tagx="given-names" title="given-names">H.E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Barreiro</span><span class="given-names" tagx="given-names" title="given-names">L.B.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Herd Immunity: Understanding COVID-19</span><span class="source" tagx="source" title="source">Immunity</span><span class="volume" tagx="volume" title="volume">52</span><span class="issue" tagx="issue" title="issue">5</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">737</span><span class="lpage" tagx="lpage" title="lpage">741</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32433946">32433946</a></span></span></li> <li tag="ref"><a name="b0355" /><span class="label" tagx="label" title="label">71</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bao</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Reinfection could not occur in SARS-CoV-2 infected rhesus macaques</span><span class="source" tagx="source" title="source">BioRxiv</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0360" /><span class="label" tagx="label" title="label">72</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wu</span><span class="given-names" tagx="given-names" title="given-names">L.-P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Duration of antibody responses after severe acute respiratory syndrome</span><span class="source" tagx="source" title="source">Emerging infectious diseases</span><span class="volume" tagx="volume" title="volume">13</span><span class="issue" tagx="issue" title="issue">10</span><span class="year" tagx="year" title="year">2007</span><span class="fpage" tagx="fpage" title="fpage">1562</span><span class="lpage" tagx="lpage" title="lpage">1564</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18258008">18258008</a></span></span></li> <li tag="ref"><a name="b0365" /><span class="label" tagx="label" title="label">73</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">W.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome</span><span class="source" tagx="source" title="source">The Journal of infectious diseases</span><span class="volume" tagx="volume" title="volume">193</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2006</span><span class="fpage" tagx="fpage" title="fpage">792</span><span class="lpage" tagx="lpage" title="lpage">795</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16479513">16479513</a></span></span></li> <li tag="ref"><a name="b0370" /><span class="label" tagx="label" title="label">74</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cao</span><span class="given-names" tagx="given-names" title="given-names">W.-C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery</span><span class="source" tagx="source" title="source">New England Journal of Medicine</span><span class="volume" tagx="volume" title="volume">357</span><span class="issue" tagx="issue" title="issue">11</span><span class="year" tagx="year" title="year">2007</span><span class="fpage" tagx="fpage" title="fpage">1162</span><span class="lpage" tagx="lpage" title="lpage">1163</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17855683">17855683</a></span></span></li> <li tag="ref"><a name="b0375" /><span class="label" tagx="label" title="label">75</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients</span><span class="source" tagx="source" title="source">Scand J Infect Dis</span><span class="volume" tagx="volume" title="volume">43</span><span class="issue" tagx="issue" title="issue">6â€"7</span><span class="year" tagx="year" title="year">2011</span><span class="fpage" tagx="fpage" title="fpage">515</span><span class="lpage" tagx="lpage" title="lpage">521</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21366405">21366405</a></span></span></li> <li tag="ref"><a name="b0380" /><span class="label" tagx="label" title="label">76</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhu</span><span class="given-names" tagx="given-names" title="given-names">F.-C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</span><span class="source" tagx="source" title="source">The Lancet</span><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="b0385" /><span class="label" tagx="label" title="label">77</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Moderna, Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus. 2020, Moderna, Inc.</span></li> <li tag="ref"><a name="b0390" /><span class="label" tagx="label" title="label">78</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gouglas</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study</span><span class="source" tagx="source" title="source">The Lancet. Global health</span><span class="volume" tagx="volume" title="volume">6</span><span class="issue" tagx="issue" title="issue">12</span><span class="year" tagx="year" title="year">2018</span><span class="fpage" tagx="fpage" title="fpage">e1386</span><span class="lpage" tagx="lpage" title="lpage">e1396</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30342925">30342925</a></span></span></li> <li tag="ref"><a name="b0395" /><span class="label" tagx="label" title="label">79</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mullard</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">COVID-19 vaccine development pipeline gears up</span><span class="source" tagx="source" title="source">The Lancet</span><span class="volume" tagx="volume" title="volume">395</span><span class="issue" tagx="issue" title="issue">10239</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1751</span><span class="lpage" tagx="lpage" title="lpage">1752</span></span></li> <li tag="ref"><a name="b0400" /><span class="label" tagx="label" title="label">80</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">World Health Organisation. Update on WHO Solidarity Trial â€" Accelerating a safe and effective COVID-19 vaccine. 2020 [cited 2020 May 24, 2020]; Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine.</span></li> <li tag="ref"><a name="b0405" /><span class="label" tagx="label" title="label">81</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">National Institutes of Health. NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options. 2020 April 17, 2020 [cited 2020 May 24, 2020]; Available from: https://www.nih.gov/news-events/news-releases/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-options.</span></li> <li tag="ref"><a name="b0410" /><span class="label" tagx="label" title="label">82</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parashar</span><span class="given-names" tagx="given-names" title="given-names">U.D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Value of post-licensure data on benefits and risks of vaccination to inform vaccine policy: The example of rotavirus vaccines</span><span class="source" tagx="source" title="source">Vaccine</span><span class="volume" tagx="volume" title="volume">33</span><span class="issue" tagx="issue" title="issue">Suppl 4</span><span class="year" tagx="year" title="year">2015</span><span class="fpage" tagx="fpage" title="fpage">D55</span><span class="lpage" tagx="lpage" title="lpage">D59</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26122581">26122581</a></span></span></li> <li tag="ref"><a name="b0415" /><span class="label" tagx="label" title="label">83</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yen</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Rotavirus vaccination and intussusception - Science, surveillance, and safety: A review of evidence and recommendations for future research priorities in low and middle income countries</span><span class="source" tagx="source" title="source">Human vaccines &amp;amp; immunotherapeutics</span><span class="volume" tagx="volume" title="volume">12</span><span class="issue" tagx="issue" title="issue">10</span><span class="year" tagx="year" title="year">2016</span><span class="fpage" tagx="fpage" title="fpage">2580</span><span class="lpage" tagx="lpage" title="lpage">2589</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27322835">27322835</a></span></span></li> <li tag="ref"><a name="b0420" /><span class="label" tagx="label" title="label">84</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Larson</span><span class="given-names" tagx="given-names" title="given-names">H.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hartigan-Go</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Figueiredo</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Vaccine confidence plummets in the Philippines following dengue vaccine scare: why it matters to pandemic preparedness</span><span class="source" tagx="source" title="source">Hum Vaccin Immunother</span><span class="volume" tagx="volume" title="volume">15</span><span class="issue" tagx="issue" title="issue">3</span><span class="year" tagx="year" title="year">2019</span><span class="fpage" tagx="fpage" title="fpage">625</span><span class="lpage" tagx="lpage" title="lpage">627</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30309284">30309284</a></span></span></li> <li tag="ref"><a name="b0425" /><span class="label" tagx="label" title="label">85</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Bruin</span><span class="given-names" tagx="given-names" title="given-names">Y.B.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemic</span><span class="source" tagx="source" title="source">Safety Science</span><span class="year" tagx="year" title="year">2020</span>104773</span></li> <li tag="ref"><a name="b0430" /><span class="label" tagx="label" title="label">86</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">World Health</span></span></span><span class="chapter-title" tagx="chapter-title" title="chapter-title">Organization and Global Polio Eradication Initiative, <i>Polio endgame strategy 2019â€"2023: eradication, integration, certification and containment</i></span><span class="year" tagx="year" title="year">2019</span><span class="publisher-name" tagx="publisher-name" title="publisher-name">World Health Organization</span></span></li> <li tag="ref"><a name="b0435" /><span class="label" tagx="label" title="label">87</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lewis</span><span class="given-names" tagx="given-names" title="given-names">I.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A Supply and Demand Management Perspective on the Accelerated Global Introductions of Inactivated Poliovirus Vaccine in a Constrained Supply Market</span><span class="source" tagx="source" title="source">The Journal of Infectious Diseases</span><span class="volume" tagx="volume" title="volume">216</span><span class="issue" tagx="issue" title="issue">suppl_1</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">S33</span><span class="lpage" tagx="lpage" title="lpage">S39</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28838159">28838159</a></span></span></li> <li tag="ref"><a name="b0440" /><span class="label" tagx="label" title="label">88</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Chinese Clinical Trial Registry. ChiCTR2000030906 A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector) 2020 [cited 2020 25 May 2020]; Available from: http://www.chictr.org.cn/showprojen.aspx?proj=51154.</span></li> <li tag="ref"><a name="b0445" /><span class="label" tagx="label" title="label">89</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT04313127. Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults (CTCOVID-19) 2020 [cited 2020 25 May 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04313127.</span></li> <li tag="ref"><a name="b0450" /><span class="label" tagx="label" title="label">90</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Chinese Clinical Trial Registry. ChiCTR2000031781 A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) 2020 [cited 2020 25 May 2020]; Available from: http://www.chictr.org.cn/showprojen.aspx?proj=52006.</span></li> <li tag="ref"><a name="b0455" /><span class="label" tagx="label" title="label">91</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT04341389. A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV) 2020 [cited 2020 May 25 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04341389.</span></li> <li tag="ref"><a name="b0460" /><span class="label" tagx="label" title="label">92</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT04324606. A Study of a Candidate COVID-19 Vaccine (COV001) 2020 [cited 2020 25 May 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04324606.</span></li> <li tag="ref"><a name="b0465" /><span class="label" tagx="label" title="label">93</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT04352608. Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19) 2020 April 28, 2020 [cited 2020 May 25, 2020].</span></li> <li tag="ref"><a name="b0470" /><span class="label" tagx="label" title="label">94</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT04383574. Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19) 2020 12 May 2020 [cited 2020 25 May 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04383574.</span></li> <li tag="ref"><a name="b0475" /><span class="label" tagx="label" title="label">95</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Chinese Clinical Trial Registry. ChiCTR2000031809 A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells) 2020 April 13, 2020 [cited 2020 May 25, 2020]; Available from: http://www.chictr.org.cn/showprojen.aspx?proj=52227.</span></li> <li tag="ref"><a name="b0480" /><span class="label" tagx="label" title="label">96</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT04368988. Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant 2020 May 15, 2020 [cited 2020 May 25, 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04368988.</span></li> <li tag="ref"><a name="b0485" /><span class="label" tagx="label" title="label">97</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">EU Clinical Trials Register. EudraCT Number: 2020-001038-36. A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens 2020 April 20, 2020 [cited 2020 May 25, 2020]; Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-001038-36.</span></li> <li tag="ref"><a name="b0490" /><span class="label" tagx="label" title="label">98</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT04336410. 2020 April 24, 2020 [cited 2020 May 2, 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04336410.</span></li> <li tag="ref"><a name="b0495" /><span class="label" tagx="label" title="label">99</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">ClinicalTrials.gov. Identifier: NCT04334980. 2020 April 22, 2020 [cited 2020 May 25, 2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04334980.</span></li> <li tag="ref"><a name="b0500" /><span class="label" tagx="label" title="label">100</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">C.Y.-P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Serological Approaches for COVID- 19: Epidemiologic Perspective on Surveillance and Control</span><span class="source" tagx="source" title="source">Frontiers in Immunology</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">11(879)</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32082309">32082309</a></span></span></li> </ul> </div> </div>  </body></html>